8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia

8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia

Core Knowledge: Managing severe thermal injury pain solely with escalating doses of opioid monotherapy is obsolete, ineffective, and clinically hazardous. High-dose opioid monotherapy inevitably leads to rapid pharmacological tolerance, bowel hypomotility / paralytic ileus, severe sedation, respiratory depression, and Opioid-Induced Hyperalgesia (OIH). In alignment with American Burn Association (ABA) Clinical Practice Guidelines, the standard of care is a structured multimodal analgesia paradigm that combines pharmacological agents with complementary mechanisms of action acting across different anatomical and neurochemical pathways.

---

1. The Multimodal Analgesia Paradigm in Thermal Injury

Multimodal analgesia achieves pharmacological synergy: by combining lower doses of diverse analgesic classes, clinicians optimize pain relief across all four neurobiological stages of nociception while significantly blunting drug-specific adverse effects.

                      MULTIMODAL PHARMACOLOGICAL TARGETS
  ┌────────────────────────────────────────────────────────────────────────┐
  │ [1] TRANSDUCTION (Peripheral Nociceptor Activation)                    │
  │     • NSAIDs & Acetaminophen ──► Inhibit Cyclooxygenase (COX-1/COX-2)  │
  │     • Topical Lidocaine ───────► Blocks Voltage-Gated Na+ Channels    │
  ├────────────────────────────────────────────────────────────────────────┤
  │ [2] TRANSMISSION (Peripheral Nerve to Dorsal Horn)                     │
  │     • Regional Nerve Blocks ───► Local anesthetics halt action pot.    │
  │     • Gabapentinoids ──────────► Block α2δ Subunit of Presynaptic Ca2+ │
  ├────────────────────────────────────────────────────────────────────────┤
  │ [3] MODULATION (Dorsal Horn Spinal Processing & Wind-Up)               │
  │     • Ketamine & Methadone ────► NMDA Receptor Antagonism (Anti-Windup)│
  │     • Alpha-2 Agonists ────────► Precedex / Clonidine augment descending│
  │                                  inhibitory noradrenergic pathways     │
  ├────────────────────────────────────────────────────────────────────────┤
  │ [4] PERCEPTION (Thalamic, Limbic & Somatosensory Cortical Processing)  │
  │     • Opioids (Fentanyl/Morph) ─► Mu (μ) Opioid Receptor Agonism       │
  │     • Dexmedetomidine ─────────► Locus coeruleus sedative-analgesia    │
  └────────────────────────────────────────────────────────────────────────┘

---

2. Opioid Analgesics in Burn Care

Opioids remain the cornerstone of acute burn analgesia for severe background and procedural pain. However, pharmacokinetic profiles dictate distinct clinical applications.

Patient-Controlled Analgesia (PCA) Rules & Safety Benchmarks

Patient-Controlled Analgesia empowers communicative, cognitively intact burn patients to titrate intravenous analgesia directly to their comfort level:

• Demand (Bolus) Dose: Standard prescribed aliquot (e.g., Hydromorphone 0.2–0.4 mg or Morphine 1–2 mg) delivered upon button press.
• Lockout Interval: Programmed refractory window (typically 6 to 10 minutes) preventing delivery of another dose until the previous dose reaches peak clinical effect, preventing stacking and inadvertent overdose.
• Continuous Basal Rate Controversy: Continuous basal infusions on PCA pumps in opioid-naive patients significantly increase the risk of nocturnal hypoventilation, severe respiratory depression, and fatal overdose. Basal rates should be restricted to opioid-tolerant burn patients with documented high resting background pain.
• Monitoring Standards: Continuous pulse oximetry and end-tidal capnography ($EtCO_2$) are mandatory for patients receiving continuous basal PCA or high-dose opioid regimens to detect early hypoventilation prior to pulse oximetry desaturation.
• "PCA by Proxy" Prohibition: Family members, visitors, and bedside staff are strictly prohibited from pressing the PCA button on behalf of a sleeping or sedated patient. The patient's own waking state and cognitive drive serve as the primary physiological safety barrier against fatal overdose.

---

3. Sub-Anesthetic Ketamine: NMDA Receptor Blockade

Ketamine is a phencyclidine (PCP) derivative that has revolutionized burn pain management. At sub-anesthetic dosages (0.1 to 0.5 mg/kg IV bolus or 0.1 to 0.2 mg/kg/hr continuous infusion), ketamine functions as a potent analgesic and anti-hyperalgesic agent rather than a general anesthetic.

                      KETAMINE MECHANISM & CLINICAL UTILITY
  ┌────────────────────────────────────────────────────────────────────────┐
  │                    NON-COMPETITIVE NMDA ANTAGONISM                     │
  ├────────────────────────────────────────────────────────────────────────┤
  │ • Binds the phencyclidine site inside the open NMDA receptor channel  │
  │ • Blocks calcium influx into dorsal horn Wide Dynamic Range neurons    │
  │ • Halts spinal "Wind-Up" and reverses central sensitization           │
  │ • PREVENTS & REVERSES Opioid-Induced Hyperalgesia (OIH)                │
  ├────────────────────────────────────────────────────────────────────────┤
  │                    UNIQUE PHYSIOLOGICAL ADVANTAGES                    │
  ├────────────────────────────────────────────────────────────────────────┤
  │ • Preserves pharyngeal/laryngeal protective airway reflexes            │
  │ • Maintains spontaneous minute ventilation (minimal respiratory depr.)│
  │ • Bronchodilation (beneficial in smoke inhalation / reactive airway)   │
  │ • Sympathomimetic release of catecholamines (supports BP & HR)         │
  ├────────────────────────────────────────────────────────────────────────┤
  │                    MANAGEMENT OF PSYCHOMIMETIC EFFECTS                │
  ├────────────────────────────────────────────────────────────────────────┤
  │ • Emergence reactions, vivid dreams, hallucinations, and dysphoria     │
  │ • Mitigated by co-administering low-dose Midazolam (1–2 mg IV) or      │
  │   Dexmedetomidine (Precedex)                                           │
  └────────────────────────────────────────────────────────────────────────┘

Opioid-Induced Hyperalgesia (OIH) vs. Pharmacological Tolerance

A critical diagnostic competency for the CBRN is differentiating Opioid-Induced Hyperalgesia (OIH) from Opioid Tolerance in burn patients receiving escalating opioid doses:

• Tolerance: Characterized by a rightward shift of the dose-response curve; increasing the opioid dose successfully restores analgesic efficacy.
• Opioid-Induced Hyperalgesia (OIH): A paradoxical state wherein escalating opioid administration actually worsens pain sensitivity, expanding allodynia and hyperalgesia to unburned anatomical regions. Driven by neurotoxic opioid metabolites (such as morphine-3-glucuronide) and massive spinal NMDA receptor activation. Increasing the opioid dose worsens the pain. The definitive treatment is adding sub-anesthetic ketamine or transitioning to methadone to block NMDA channels, while reducing the total opioid burden.

---

4. Gabapentinoids and Membrane Stabilizers

Neuropathic pain, graft donor site dysesthesias, and debilitating post-burn pruritus are mediated by damaged cutaneous nerve terminals. Gabapentinoids (Gabapentin and Pregabalin) are foundational first-line agents in the ABA multimodal bundle:

• Mechanism of Action: Selectively bind to the $\alpha_2\delta-1$ auxiliary subunit of presynaptic voltage-gated calcium channels in the dorsal horn and brain. This binding blocks calcium influx, dramatically reducing the exocytotic release of excitatory neurotransmitters (glutamate, substance P, CGRP, and norepinephrine).
• Clinical Indications: First-line for post-burn neuropathic pain, shooting/electric sensations during scar maturation, deep donor site aching, and neuropathic post-burn pruritus. Demonstrates profound opioid-sparing efficacy (often reducing total daily morphine milligram equivalents [MME] by 30% to 50%).
• Dosing & Titration: Gabapentin is initiated at 100–300 mg PO three times daily and titrated upward (maximum 3,600 mg/day). Pregabalin is dosed at 50–150 mg PO twice or three times daily (maximum 600 mg/day).
• Critical Nursing Precaution: Gabapentinoids are cleared almost 100% unchanged by the kidneys. In burn patients with acute kidney injury (AKI) or fluctuating creatinine clearance, strict dosage reductions are mandatory to prevent neurotoxicity, profound somnolence, myoclonus, and respiratory depression when combined with opioids.

---

5. Non-Opioid Adjuncts, Alpha-2 Agonists, and Regional Anesthesia

Non-Opioid Adjuncts

• Acetaminophen (IV / Oral): Inhibits central prostaglandin synthesis through COX-3 / peroxidase enzyme inhibition and activates descending serotonergic inhibitory pathways. Administered as a scheduled baseline non-opioid (1,000 mg IV/PO q6h; maximum 4,000 mg/24h in normal adults; restricted to $\le 2,000\text{–}3,000\text{ mg/day}$ in patients with hepatic dysfunction, chronic alcohol abuse, or severe malnutrition).
• NSAIDs (Ketorolac, Ibuprofen, Celecoxib): Block peripheral cyclooxygenase (COX-1 and COX-2) enzymes, reducing inflammatory prostaglandin synthesis and tissue edema. High Caution in Acute Resuscitation: NSAIDs are strictly contraindicated during the initial 48-hour resuscitation phase and in unstable burn shock due to the high risk of compounding acute renal tubular hypoperfusion (blocking compensatory renal prostacyclin vasodilation), triggering GI bleeding / Curling's ulcers, and inducing platelet dysfunction prior to surgical excision.
• Alpha-2 Adrenergic Agonists (Dexmedetomidine & Clonidine):
  • Dexmedetomidine (Precedex): Highly selective central $\alpha_2$ agonist acting on the locus coeruleus. Provides "cooperative sedation" where patients remain easily arousable, anxiolysis, and significant opioid-sparing analgesia without causing respiratory depression. Ideal for mechanically ventilated burn patients, agitated delirium, and procedural dressing changes. Requires continuous monitoring for bradycardia and hypotension.
  • Clonidine: Oral $\alpha_2$ agonist valuable for mitigating autonomic storming, treating neuropathic background pain, and managing opioid weaning in prolonged ICU stays.

Regional Anesthesia and Peripheral Nerve Blocks

Targeted peripheral nerve blocks deliver dense, localized anesthesia directly to surgical and donor sites, eliminating systemic side effects:

• Fascia Iliaca Compartment Block (FICB) & Femoral Nerve Block: Infiltrates local anesthetic (e.g., ropivacaine, bupivacaine) beneath the fascia iliaca, bathing the femoral, lateral femoral cutaneous, and obturator nerves. Serves as the gold standard for anterior/lateral thigh split-thickness skin graft (STSG) donor site harvesting, providing 12 to 24 hours of near-complete site-specific analgesia.
• Transversus Abdominis Plane (TAP) Block: Deposits local anesthetic in the fascial plane between the internal oblique and transversus abdominis muscles, providing profound analgesia for trunk/abdominal burn excision or donor harvesting.
• Continuous Peripheral Nerve Catheters: Perineural infusion of dilute local anesthetics delivers days of targeted analgesia, dramatically reducing systemic opioid consumption and facilitating aggressive physical therapy joint mobilization.